Trulieve Cannabis (F09) Stock Forecast & Price Target

18 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

F09 Analyst Ratings

Strong Buy

3 Buy

0 Hold

0 Sell

Based on 3 analysts giving stock ratings to

Trulieve

Cannabis

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

F09 Stock 12 Month Forecast

Average Price Target

€16.09

▲(72.32% Upside)

Based on 3 Wall Street analysts offering 12 month price targets for Trulieve Cannabis in the last 3 months. The average price target is €16.09 with a high forecast of €17.17 and a low forecast of €14.81. The average price target represents a 72.32% change from the last price of €9.34.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","6":"€6","10":"€10","14":"€14","18":"€18"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":17.167205199999998,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€17.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.094254875,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€16.09</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.806714485,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€14.81</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,6,10,14,18],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.3,8.059015784615385,8.818031569230769,9.577047353846153,10.336063138461537,11.095078923076922,11.854094707692306,12.61311049230769,13.372126276923076,14.131142061538458,14.890157846153844,15.64917363076923,16.408189415384612,{"y":17.167205199999998,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.3,7.976481144230769,8.652962288461538,9.329443432692308,10.005924576923077,10.682405721153845,11.358886865384616,12.035368009615384,12.711849153846153,13.388330298076923,14.064811442307693,14.74129258653846,15.41777373076923,{"y":16.094254875,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.3,7.87743957576923,8.454879151538462,9.032318727307691,9.609758303076923,10.187197878846153,10.764637454615384,11.342077030384615,11.919516606153845,12.496956181923077,13.074395757692308,13.651835333461538,14.229274909230769,{"y":14.806714485,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.74,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.385,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.9,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.865,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.55,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.605,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.88,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.385,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.746,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.23,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.81,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.1,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.3,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€17.17

Average Price Target€16.09

Lowest Price Target€14.81

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Neal Gilmer

Haywood

€14.81

Buy

58.53%

Upside

Reiterated

08/07/26

Analysts' Top Healthcare Picks: COMPASS Pathways (CMPS), Trulieve Cannabis (TRLV)

Aaron Grey

Alliance Global Partners

€17.17

Buy

83.80%

Upside

Reiterated

08/07/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Gabrielle Ingoglia

Cantor Fitzgerald

Not Ranked

Cantor Fitzgerald

€12.88

Buy

37.85%

Upside

Initiated

07/20/26

Trulieve Cannabis initiated with an Overweight at Cantor FitzgeraldTrulieve Cannabis initiated with an Overweight at Cantor Fitzgerald

Bill Kirk

Roth MKM

€16.31

Buy

74.61%

Upside

Reiterated

06/05/26

Trulieve Cannabis (TCNNF) Gets a Buy from Roth MKM

Luke Hannan

Canaccord Genuity

€17.35

Buy

85.73%

Upside

Reiterated

05/08/26

Canaccord Genuity Reaffirms Their Buy Rating on Trulieve Cannabis (TCNNF)

Frederico Gomes

ATB Cormark Capital Markets

€9.29

Buy

-0.50%

Downside

Reiterated

02/27/26

Analysts' Top Healthcare Picks: Trulieve Cannabis (TCNNF), Medline (MDLN)

Russell Stanley

Beacon

€12.39

Buy

32.67%

Upside

Reiterated

12/22/25

This weed stock is a buy, analyst saysBeacon Securities analyst Russell Stanley reiterated his Buy rating and C$20.00 target on Trulieve Cannabis (Trulieve Cannabis Stock Quote, Chart, News, Analysts, Financials CSE:TRUL) on Dec. 17, after the company closed an upsized private placement of senior secured notes that Stanley said underscores strong investor demand and further strengthens the balance sheet.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Neal Gilmer

Haywood

€14.81

Buy

58.53%

Upside

Reiterated

08/07/26

Analysts' Top Healthcare Picks: COMPASS Pathways (CMPS), Trulieve Cannabis (TRLV)

Aaron Grey

Alliance Global Partners

€17.17

Buy

83.80%

Upside

Reiterated

08/07/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Gabrielle Ingoglia

Cantor Fitzgerald

Not Ranked

Cantor Fitzgerald

€12.88

Buy

37.85%

Upside

Initiated

07/20/26

Trulieve Cannabis initiated with an Overweight at Cantor FitzgeraldTrulieve Cannabis initiated with an Overweight at Cantor Fitzgerald

Bill Kirk

Roth MKM

€16.31

Buy

74.61%

Upside

Reiterated

06/05/26

Trulieve Cannabis (TCNNF) Gets a Buy from Roth MKM

Luke Hannan

Canaccord Genuity

€17.35

Buy

85.73%

Upside

Reiterated

05/08/26

Canaccord Genuity Reaffirms Their Buy Rating on Trulieve Cannabis (TCNNF)

Frederico Gomes

ATB Cormark Capital Markets

€9.29

Buy

-0.50%

Downside

Reiterated

02/27/26

Analysts' Top Healthcare Picks: Trulieve Cannabis (TCNNF), Medline (MDLN)

Russell Stanley

Beacon

€12.39

Buy

32.67%

Upside

Reiterated

12/22/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ODTXOdyssey Therapeutics, Inc.

BTSGBrightSpring Health Services, Inc.

GPCRStructure Therapeutics, Inc. Sponsored ADR

AMLXAmylyx Pharmaceuticals Inc

IMMXImmix Biopharma

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Trulieve Cannabis

3 Months

Russell StanleyBeacon

Success Rate

9/16 ratings generated profit

Average Return

+10.57%

Copying Russell Stanley's trades and holding each position for 3 Months would result in 56.25% of your transactions generating a profit, with an average return of +10.57% per trade.

1 Year

Russell StanleyBeacon

Success Rate

9/16 ratings generated profit

Average Return

+56.69%

Copying Russell Stanley's trades and holding each position for 1 Year would result in 56.25% of your transactions generating a profit, with an average return of +56.69% per trade.

2 Years

Russell StanleyBeacon

Success Rate

11/16 ratings generated profit

Average Return

+111.61%

Copying Russell Stanley's trades and holding each position for 2 Years would result in 68.75% of your transactions generating a profit, with an average return of +111.61% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

F09 Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, F09 has received 5 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. F09 average Analyst price target in the past 3 months is 16.09.

Each month's total comprises the sum of three months' worth of ratings.

F09 Financial Forecast

F09 Earnings Forecast

Next quarter’s earnings estimate for F09 is €0.08 with a range of €0.02 to €0.10. The previous quarter’s EPS was -€1.80. F09 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year F09 has Performed in-line its overall industry.

F09 Sales Forecast

Next quarter’s sales forecast for F09 is €189.78M with a range of €189.04M to €189.98M. The previous quarter’s sales results were €231.77M. F09 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year F09 has Performed in-line its overall industry.

F09 Stock Forecast FAQ

What is DE:F09’s average 12-month price target, according to analysts?

Based on analyst ratings, Trulieve Cannabis’s 12-month average price target is 16.09.

What is DE:F09’s upside potential, based on the analysts’ average price target?

Trulieve Cannabis has 72.32% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Trulieve Cannabis a Buy, Sell or Hold?

Trulieve Cannabis has a consensus rating of Strong Buy, which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.

What is Trulieve Cannabis’s share price target?

The average share price target for Trulieve Cannabis is 16.09. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €17.17 ,and the lowest forecast is €14.81. The average share price target represents 72.32% Increase from the current price of €9.34.

What do analysts say about Trulieve Cannabis?

Trulieve Cannabis’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of Trulieve Cannabis?

To buy shares of DE:F09, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Trulieve Cannabis (F09) Stock Forecast & Price Target

F09 Analyst Ratings

F09 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Trulieve Cannabis

F09 Analyst Recommendation Trends

F09 Financial Forecast

F09 Earnings Forecast

F09 Sales Forecast

F09 Stock Forecast FAQ

Detailed List of Analyst Forecasts